Clinical Trials Logo

Lymphoma, T-Cell clinical trials

View clinical trials related to Lymphoma, T-Cell.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT05131438 No longer available - Clinical trials for Extranodal NK/T-cell Lymphoma

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

Start date: n/a
Phase:
Study type: Expanded Access

This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.

NCT ID: NCT01196208 No longer available - Clinical trials for Lymphoma, Non-Hodgkin

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001

NCT ID: NCT00419367 No longer available - Clinical trials for Lymphoma, T-Cell, Cutaneous

Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)

Start date: n/a
Phase:
Study type: Expanded Access

In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the SPONSOR (e.g. Named Patient Program (NPP)). For those institutions that do not allow receipt of an investigational therapy outside of a clinical trial, patients that are actively receiving study medication and continue to meet eligibility will transition to an extension phase of the study and the base study will be closed. The extension phase will begin as soon as the protocol amendment is implemented.